Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622), has seen a significant stock price increase of over 35% this week, with a current price of HKD 3.78 and a trading volume of HKD 22.5882 million, following the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Group 1: Product Development - The TONO-i device will be a crucial part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - TONO-i provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, which aids in delivering immediate and continuous feedback on treatment efficacy, thereby improving patient compliance with glaucoma medication [1] - The introduction of TONO-i into the company's pipeline signifies its commitment to a dual approach in glaucoma management, focusing on both treatment and diagnosis [1] Group 2: Distribution Agreement - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of developing diagnostic, therapeutic, and preventive medical devices for glaucoma [1] - Under the terms of the agreement, the company holds exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which were later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 7% and nearly 35% this week, indicating strong market interest and confidence in the company's future prospects [1] Company Developments - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, which will be a key part of its glaucoma medical product portfolio [1] - TONO-i is designed to provide ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, thereby improving patient adherence to glaucoma medication treatment [1] - The introduction of TONO-i into the company's pipeline underscores its commitment to dual approaches in glaucoma management, focusing on both treatment and diagnosis [1] Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - The company, Zhaoke Ophthalmology-B (6622.HK), has seen a significant stock price increase of 17.36%, reaching HKD 3.65, potentially marking a new closing high since January 4, 2024 [1] Group 1: Product Development - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, which will be a key part of its glaucoma product portfolio [1] - TONO-i aims to address the demand gap in China for low diagnosis and treatment rates in glaucoma management, indicating the company's commitment to dual approaches in treatment and diagnosis [1] Group 2: Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the development of medical devices for the diagnosis, treatment, and prevention of glaucoma [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, attributed to the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Company Developments - The company reported a stock price increase of over 10%, with a current price of 3.4 HKD and a trading volume of 11.32 million HKD [1] - TONO-i will be a key part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - The device provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, enhancing patient compliance with glaucoma medication [1] Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which has since been expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 10% and currently trading at 3.4 HKD, with a transaction volume of 11.32 million HKD, following the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Group 1: Product Development - The TONO-i device will be a crucial part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - TONO-i provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, facilitating immediate and continuous feedback on treatment efficacy, thereby improving patient compliance with glaucoma medication [1] Group 2: Distribution Agreement - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of developing diagnostic, therapeutic, and preventive medical devices for glaucoma [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, marking a significant advancement in its glaucoma product portfolio [1] Group 1: Product Overview - TONO-i is an innovative, non-contact, portable, and lightweight tonometer designed for painless and infection-free use without anesthesia [1] - The device aims to address the low diagnosis and treatment rates for glaucoma in China, providing a crucial tool for ophthalmologists to monitor patients' intraocular pressure accurately and continuously [1] Group 2: Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&V Tech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, marking a significant advancement in its glaucoma product portfolio [1] Group 1: Product Overview - TONO-i is an innovative, non-contact, portable, and lightweight tonometer designed for painless and infection-free use without anesthesia [1] - The device aims to address the low diagnosis and treatment rates for glaucoma in China, providing a tool for ophthalmologists to easily and accurately monitor patients' intraocular pressure [1] Group 2: Market Strategy - TONO-i will play a crucial role in the company's commitment to glaucoma management through both treatment and diagnosis [1] - In November 2022, the company entered into an exclusive distribution agreement with C&V Tech, a leading company in the field of glaucoma diagnostic and treatment medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - The company has received a medical device registration certificate for TONO-i from the National Medical Products Administration, marking a significant advancement in its glaucoma product portfolio [1] Group 1: Product Overview - TONO-i is an innovative, non-contact, portable, and lightweight tonometer designed for painless and infection-free use without anesthesia [1] - The device aims to address the low diagnosis and treatment rates for glaucoma in China, providing an essential tool for ophthalmologists to monitor intraocular pressure accurately and continuously [1] Group 2: Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic and treatment medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which has since been expanded to include Thailand and Malaysia, effective from August 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited （於英屬處女群島註冊成立並於開曼群島存續的有限公司） （股份代號：6622） 兆科眼科有限公司 自 願 性 公 告－ 向國家藥品監督管理局取得供測量眼壓的 TONO-i的醫療器械註冊證 本 公 告 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 – 1 – 關於青光眼 按 照 灼 識 諮 詢，青 光 眼 是 全 球 第 二 位 的 致 盲 因 素，是 一 種 與 高 眼 壓 導 致 視 神 經 損 傷 相 關 的 慢 性 及 漸 進 性 疾 病。眼 壓 由 眼 內 房 水 產 生 與 房 水 排 放 比 率 的 平 衡 決 定。幾 乎 所 有 的 青 光 眼 個 案 為 原 發 性 青 光 眼，通 常 可 分 為 開 角 型 青 光 眼 及 閉 角 ...

Core Viewpoint - The company Zhaoke Ophthalmology (06622) has seen a significant stock price increase following the announcement of receiving orphan drug designation (ODD) from the FDA for its proprietary formulation, Mephalan, aimed at treating retinoblastoma in children, which could lead to exclusive market rights in the U.S. for seven years if approved [1] Group 1 - Zhaoke Ophthalmology's stock rose over 9% during trading, with a current increase of 5.59%, reaching HKD 3.02, and a trading volume of HKD 12.43 million [1] - The FDA granted orphan drug designation (ODD) for Mephalan, establishing a clear regulatory pathway for the company to submit a new drug clinical trial application in the U.S. [1] - If Mephalan is successfully developed and approved, the company will enjoy seven years of exclusive rights in the U.S. market post-approval, including data exclusivity and market authorization holder status [1] Group 2 - Zhaoke Ophthalmology recently announced a strategic partnership with FAREVA, a leading French pharmaceutical company, to become a trusted partner for drug manufacturing in China [1] - The memorandum of understanding signed with FAREVA indicates Zhaoke Ophthalmology's role as a recommended partner for FAREVA's clients seeking drug production in China [1]